After his inauguration, President Donald J. Trump signed an executive order ordering federal agencies to ease the burden of his predecessor’s landmark healthcare law.
During his campaign, President Donald J. Trump promised that repealing the Affordable Care Act (ACA) would be the first order of business, and he kept that promise. After his inauguration, Trump signed an executive order ordering federal agencies to ease the burden of his predecessor’s landmark healthcare law.
The executive order outlined the intent for a “prompt repeal” of the ACA and until the law is repealed, Trump is calling for taking “all actions consistent with law to minimize the unwarranted economic and regulatory burdens of the Act.”
The order also called for easing financial and regulatory burdens on states, individuals and families, health insurers, healthcare providers, and other stakeholders through waiving, deferring, granting exemptions, and delaying the implementing of provisions of the ACA. According to the AP, this aspect of the executive order is aimed at the unpopular individual mandate, which requires individuals to purchase health insurance or pay a penalty.
The order directs federal agencies to stop issuing regulations to expand the law, and also directs the secretary of HHS and agencies to “provide greater flexibility to states and cooperate with them in implementing healthcare programs.”
The AP reported that the effect of this executive order on the ACA could take weeks to fully understand. Uncertainty remains as to what to expect of the impact on not only the individual insurance market, but the coverage status of millions of Americans—especially those of a lower socioeconomic status or with preexisting conditions, who could face a loss of coverage depending on which components of the ACA are eventually disbanded.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More